NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice
Open accessAbstract
NDV-3A, a novel fungal vaccine undergoing clinical trials, contains a recombinant version of the Candida albicans rAls3 N-terminus protein (rAls3p-N) in aluminum hydroxide. In a Phase 1b/2a clinical trial, NDV-3A protected women from recurrent vulvovaginal candidiasis. Here, we reveal that active immunization in mice with NDV-3A induces high titers of anti-rAls3p-N antibodies that interfere with C. albicans ability to adhere to and invade endothelial cells, and form biofilm in vitro. Anti-rAls3p-N antibodies also significantly inhibit yeast dispersal from the hyphal layers of biofilms. Compared to placebo, NDV-3A vaccination inhibited C. albicans dissemination to kidneys and prevented colonization of central venous catheters in mice. Overall, these preclinical studies suggest that NDV-3A may serve as an immunotherapeutic strategy for prevention of infections on indwelling medical devices.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In C. albicans, targeting adhesin proteins with vaccines decreases adhesion to and biofilm formation on plastic surfaces, invasion of vaginal epithelial cells, and virulence.
“In the model fungal pathogen C. albicans, targeting adhesin proteins with vaccines results in a decrease in adhesion to and biofilm formation on plastic surfaces, including catheters, invasion of vaginal epithelial cells, and virulence22–24.”
From Adhesin Als4112 promotes Candida auris skin colonization through interactions with keratinocytes and extracellular matrix proteins (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
<i>Candida albicans</i> Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057 · see citing works
Luo, G., Ibrahim, A. S., French, S. W., Edwards, J. E., & Fu, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025909 · Cited by 62 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 24
- [1]Ilkit M Guzel AB The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective Crit Rev Microbiol 2011 37 250 261 10.3109/1040841X.2011.576332 21599498 · DOI
- [2]Hajjeh R. A. Sofair A. N. Harrison L. H. Lyon G. M. Arthington-Skaggs B. A. Mirza S. A. Phelan M. Morgan J. Lee-Yang W. Ciblak M. A. Benjamin L. E. Thomson Sanza L. Huie S. Yeo S. F. Brandt M. E. Warnock D. W. Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program Journal of Clinical Microbiology 2004 42 4 1519 1527 10.1128/JCM.42.4.1519-1527.2004 15070998 PMC387610 · DOI · Paper page
- [3]Gudlaugsson O Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 2003 37 1172 1177 10.1086/378745 14557960 · DOI · Paper page
- [4]Tsui C Kong EF Jabra-Rizk MA Pathogenesis of Candida albicans biofilm Pathog Dis 2016 74 ftw018 10.1093/femspd/ftw018 26960943 PMC5975230 · DOI
- [5]Williams David W. Jordan Rachael P. C. Wei Xiao-Qing Alves Carlos T. Wise Matt P. Wilson Melanie J. Lewis Michael A. O. Interactions ofCandida albicanswith host epithelial surfaces Journal of Oral Microbiology 2013 5 1 22434 10.3402/jom.v5i0.22434 PMC3805843 24155995 · DOI
- [7]Pierce, C. G. et al. A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance. NPJ Biofilms Microbiomes1, 10.1038/npjbiofilms.2015.12 (2015). PMC4681527 26691764 · DOI · Paper page
- [8]Phan QT Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells PLoS Biol 2007 5 e64 10.1371/journal.pbio.0050064 17311474 PMC1802757 · DOI · Paper page
- [9]Zhao X Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces Microbiology 2006 152 2287 2299 10.1099/mic.0.28959-0 16849795 PMC2583121 · DOI
- [10]Almeida RS the hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin PLoS Pathog 2008 4 e1000217 10.1371/journal.ppat.1000217 19023418 PMC2581891 · DOI · Paper page
- [11]Edwards JE Jr. A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Clin Infect Dis 2018 66 1928 1936 10.1093/cid/ciy185 29697768 PMC5982716 · DOI · Paper page
- [12]Ibrahim AS NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response Vaccine 2013 31 5549 5556 10.1016/j.vaccine.2013.09.016 24063977 PMC3866209 · DOI
- [13]Lin L Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant Clin Vaccine Immunol 2008 15 582 584 10.1128/CVI.00427-07 18184821 PMC2268268 · DOI
- [14]Spellberg B Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity J Infect Dis 2008 197 967 971 10.1086/529204 18419471 PMC2717621 · DOI
- [15]Schmidt CS NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults Vaccine 2012 30 7594 7600 10.1016/j.vaccine.2012.10.038 23099329 PMC3513491 · DOI
- [16]Uppuluri P Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis Front Immunol 2018 9 1349 10.3389/fimmu.2018.01349 29963049 PMC6013566 · DOI · Paper page
- [18]Luo G Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target J Infect Dis 2010 201 1718 1728 10.1086/652407 20415594 PMC3933264 · DOI · Paper page
- [19]Vilanova M Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2 Immunology 2004 111 334 342 10.1111/j.1365-2567.2004.01819.x 15009435 PMC1782415 · DOI
- [20]Xin H Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis PLoS One 2012 7 e35106 10.1371/journal.pone.0035106 22563378 PMC3338514 · DOI
- [21]Xin H Cutler JE Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis Clin Vaccine Immunol 2011 18 1656 1667 10.1128/CVI.05215-11 21832099 PMC3187024 · DOI
- [22]Uppuluri P Dispersion as an important step in the Candida albicans biofilm developmental cycle PLoS Pathog 2010 6 e1000828 10.1371/journal.ppat.1000828 20360962 PMC2847914 · DOI · Paper page
- [23]Uppuluri P Lopez-Ribot JLG Forth and Colonize: Dispersal from Clinically Important Microbial Biofilms PLoS Pathog 2016 12 e1005397 10.1371/journal.ppat.1005397 26891125 PMC4758622 · DOI
- [24]Na BK Song CY Use of monoclonal antibody in diagnosis of candidiasis caused by Candida albicans: detection of circulating aspartyl proteinase antigen Clin Diagn Lab Immunol 1999 6 924 929 10548587 PMC95799
- [25]Jaffe EA Nachman RL Becker CG Minick CR Culture of human endothelial cells derived from umbilical veins Identification by morphologic and immunologic criteria. J Clin Invest 1973 52 2745 2756 10.1172/JCI107470 4355998 PMC302542 · DOI
- [26]Pierce CG A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing Nat Protoc 2008 3 1494 1500 10.1038/nport.2008.141 18772877 PMC2741160 · DOI · Paper page
Cited by
Sorted by citations
Zhao, G., Lyu, J., Veniaminova, N. A., Zarnowski, R., Mattos, E., Johnson, C. J., Quintanilla, D., Hautau, H., Hold, L. A., Xu, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60876-1 · Cited by 32 · see citing works
Self-citationZhao, G., Lyu, J., Veniaminova, N. A., Zarnowski, R., Mattos, E., Johnson, C. J., Quintanilla, D., Hautau, H., Hold, L. A., Xu, B., et al. (2025) · doi:10.1101/2025.02.13.637978 · Cited by 2 · see citing works
Self-citation
- Authors
- Alqarihi, A., Singh, S., Edwards, J. E., Ibrahim, A. S., & Uppuluri, P.
- Affiliations
- The Lundquist Institute (US)
- University of California, Los Angeles (US)
- Corresponding author
- Uppuluri, Priya
- Venue
- Scientific Reports
- Published
- 2019-04-17
- Volume
- 9
- Issue
- 1
- Pages
- 6194-6194
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC6470131
- OpenAlex
- W2935915453
- Cited by
- 45
- References
- 2
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 6 · 2023: 9 · 2022: 5 · 2021: 6 · 2020: 2 · 2019: 1
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01 AI063382)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- Candida albicans, aluminum hydroxide adjuvant, fungal vaccines, biofilm, endothelial cell adhesion, recurrent vulvovaginal candidiasis, device-related infection
- MeSH terms
- Animals, Antibodies, Fungal, Candida albicans, Cell Adhesion, Fungal Proteins, Fungal Vaccines, Humans, Recombinant Proteins, Vaccination, Infection Control, Biofilms, Mice, Central Venous Catheters
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
